ArticlePloS one2022

Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia).

Elisa Waldmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.